(Q35587171)

9 August 2017

1 reference

title

Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions (English)

1 reference

9 August 2017

Peroxisome proliferator-activated receptor-γ agonists in atherosclerosis: current evidence and future directions (English)

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

3 April 2024

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Cardiology and cardiovascular medicine

3 April 2024

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

3 April 2024

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

3 April 2024

author name string

Andrew Thomas

2

1 reference

9 August 2017

Alan Rees

3

1 reference

9 August 2017

Marc Evans

4

1 reference

9 August 2017

Aled W. Roberts

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624133

3 April 2024

language of work or name

1 reference

1 December 2003

1 reference

full work available at URL

9 August 2017

https://journals.lww.com/00041433-200312000-00004

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Current Opinion in Lipidology

3 April 2024

published in

1 reference

9 August 2017

volume

14

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

567-573

1 reference

Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study

9 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

3 April 2024

2

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

3 April 2024

4

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

3 April 2024

Metformin: An Update

8

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

The pleiotropic functions of peroxisome proliferator-activated receptor gamma

3 April 2024

9

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

The mechanisms of action of PPARs

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Inflammation in atherosclerosis

3 April 2024

12

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation

3 April 2024

13

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators

3 April 2024

14

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells

3 April 2024

15

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Antiinflammatory and antiarteriosclerotic effects of pioglitazone

3 April 2024

17

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis

3 April 2024

22

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice

3 April 2024

23

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

3 April 2024

26

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

3 April 2024

27

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

3 April 2024

28

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis

3 April 2024

29

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

3 April 2024

30

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

3 April 2024

31

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

3 April 2024

32

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques

3 April 2024

33

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

3 April 2024

34

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

3 April 2024

35

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

3 April 2024

36

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

3 April 2024

37

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial

3 April 2024

38

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

3 April 2024

39

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study.

3 April 2024

40

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study

3 April 2024

41

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis

3 April 2024

42

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group

3 April 2024

43

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study

3 April 2024

44

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

The pathogenesis of atherosclerosis: a perspective for the 1990s

3 April 2024

46

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Atherosclerosis — An Inflammatory Disease

3 April 2024

47

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Troglitazone improves endothelial dysfunction in patients with insulin resistance.

3 April 2024

48

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial

3 April 2024

49

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome

3 April 2024

50

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: a light microscopy study

3 April 2024

51

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM.

3 April 2024

52

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects

3 April 2024

53

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Rosiglitazone reduces urinary albumin excretion in type II diabetes

3 April 2024

54

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma

3 April 2024

55

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

3 April 2024

56

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Endothelins--from receptors to medicine

3 April 2024

57

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

3 April 2024

58

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension

3 April 2024

59

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

3 April 2024

61

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

3 April 2024

62

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

All-trans retinoic acid induces differentiation of ducts and endocrine cells by mesenchymal/epithelial interactions in embryonic pancreas.

3 April 2024

63

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Lipoproteins and atherogenesis

3 April 2024

64

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

3 April 2024

65

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

3 April 2024

67

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

3 April 2024

68

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

Inhibition of mitochondrial Na+-Ca2+ exchanger increases mitochondrial metabolism and potentiates glucose-stimulated insulin secretion in rat pancreatic islets

3 April 2024

69

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00004

3 April 2024

Identifiers

1 reference

9 August 2017

1 reference